Antibodies Archives

News and Trends 7 Sep 2022

Could COVID vaccine boosters become obsolete?

A team of researchers at Tel Aviv University in Israel has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and […]

September 7, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […]

September 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Aug 2022

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Aug 2022

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […]

August 26, 2022 - 2 minutesmins - By Liza Laws

Interview 19 Aug 2022

How re-engineering antibodies can prevent allergies

The California startup IgGenix is aiming to re-engineer antibodies that mediate allergic responses into antibodies that can block this response. We spoke with IgGenix’s CEO Jessica Grossman and CTO Derek Croote to understand the potential of such a therapy. Allergies are overreactions of the immune system to foreign substances that are normally harmless. Worldwide, and […]

August 19, 2022 - 9 minutesmins - By Omnia Ibrahim

News and Trends 8 Aug 2022

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […]

August 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

A biopharmaceutical company developing anti-inflammatory therapeutics announced today (July 26) that it is going to submit a request for Emergency Use Authorization (EUA). InflaRx made the announcement after encouraging interactions with the US Food and Drug Administration (FDA) at a recent meeting. The company had requested the meeting to discuss a potential EUA submission regarding […]

July 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […]

July 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Jul 2022

Trial for drug targeting cancerous tumors begins in China

A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […]

July 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […]

July 14, 2022 - 3 minutesmins - By Victor Kotsev

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

License submitted to FDA for drug to help those with large B-cell lymphoma

A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […]

July 1, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us